Common blood thinners may improve survival in COVID-19

Credit: CC0 Public Domain

Scientists from Mount Sinai found that treating hospitalized COVID-19 patients with anticoagulants—blood thinners that slow down clotting—may improve their chances of survival.

The research is published in the Journal of the American College of Cardiology and was conducted by Valentin Fuster et al.

In the study, researchers analyzed records of 2,773 confirmed COVID-19-positive patients admitted to five hospitals.

They found that hospitalized COVID-19 patients treated with anticoagulants had improved outcomes both in and out of the intensive care unit setting.

They also showed that the difference in bleeding events among patients treated with and without anticoagulants was not significant.

This research demonstrates anticoagulants taken orally, subcutaneously, or intravenously may play a major role in caring for COVID-19 patients, and these may prevent possible deadly events associated with coronavirus, including heart attack, stroke, and pulmonary embolism.

The team says using anticoagulants should be considered when patients get admitted to the ER and have tested positive for COVID-19 to possibly improve outcomes.

However, each case should be evaluated on an individualized basis to account for potential bleeding risk.

The findings are in line with other studies that show a large number of patients hospitalized with COVID-19 have developed high levels of life-threatening blood clots.

If you care about COVID, please read studies about the key to curing COVID-19, and almost half of COVID-19 survivors have a new disability.

For more information about COVID, please see recent studies about old drug that can save your life from COVID-19, and results showing vaccines may not prevent severe COVID-19 in these people.

Copyright © 2022 Knowridge Science Report. All rights reserved.